When given in lung cancer-bearing mice, it leads to a decrease in vascular endothelial growth factor (VEGF) expression level, triggered caspase activation with tumor cell apoptosis, and enhanced antiangiogenic effect that might refer to synergistic topoisomerase II inhibition and reduction of multidrug resistance (MDR) effect in A549 cells (232, 275, 277). Here, VEGFA is linked to lung carcinoma.